Issue of Equity

RNS Number : 6603P

Cirata PLC

11 December 2024

Cirata plc

("Cirata" or the "Company")

Issue of Equity & Total Voting Rights

Cirata plc (LSE: CRTA) announces that application has been made to the London Stock Exchange for 358,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") in relation to the settlement of consultancy fees and dealings are expected to commence at 8.00 a.m. on or around 16 December 2024. The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in issue following Admission will be 126,307,813. There are no Ordinary Shares held in treasury. The total number of voting rights in the Company is therefore 126,307,813. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

FTI Consulting	+44 (0)20 3727 1137
Matt Dixon / Kwaku Aning / Usama Ali

Stifel (Nomad and Joint Broker)	+44 (0)20 7710 7600
Fred Walsh / Ben Good / Sarah Wong

Panmure Liberum (Joint Broker)	+44 (0)20 3100 2000
Max Jones / John More

About Cirata

Cirata, accelerates data-driven revenue growth by automating data transfer and integration to modern cloud analytics and AI platforms without downtime or disruption. With Cirata, data leaders can leverage the power of AI and analytics across their entire enterprise data estate to freely choose analytics technologies, avoid vendor, platform, or cloud lock-in while making AI and analytics faster, cheaper, and more flexible. Cirata's portfolio of products and technology solutions make strategic adoption of modern data analytics efficient and automated. For more information about Cirata, visit www.cirata.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEQFLBFZLLEFBE